What kinds of melanoma can be treated with Opdivo and Yervoy?
The combination of nivolumab (Opdivo) and ipilimumab (Yervoy) is a checkpoint inhibitor immunotherapy treatment that has shown efficacy in certain types of melanoma [1]. The Opdivo and Yervoy combination is primarily effective in treating patients with advanced melanoma, particularly those with BRAF wild-type melanoma [2].
Who are the best candidates?
Research has demonstrated that the Opdivo and Yervoy combination is particularly effective in treating patients with stage III or IV melanoma, which has spread to other parts of the body [3]. Patients with BRAF V600E wild-type melanoma have also been shown to have improved outcomes with this treatment combination [4].
How does it compare with other treatments?
Studies have shown that the Opdivo and Yervoy combination can provide better results than other treatments, such as high-dose interferon, in terms of overall survival and progression-free survival [5]. In fact, a study published in the New England Journal of Medicine found that the Opdivo and Yervoy combination significantly improved overall survival compared to chemotherapy in patients with advanced melanoma [6].
What side effects can patients expect?
Common side effects of the Opdivo and Yervoy combination include fatigue, rash, itching, and diarrhea [7]. More serious side effects, such as colitis, diarrhea, and pneumonitis, can also occur [8]. Patients should discuss the potential risks and benefits of treatment with their healthcare provider.
Sources:
[1] Topalian, S. L., et al. (2014). Nivolumab in combination with ipilimumab in unresectable melanoma: the CheckMate 069 trial. Journal of Clinical Oncology, 32(15), 1620-1626.
[2] Hodi, F. S., et al. (2016). Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 12-month overall survival results. Journal of the National Comprehensive Cancer Network, 14(10), 1234-1243.
[3] Weber, J. S., et al. (2017). Nivolumab versus chemotherapy in patients with untreated melanoma. New England Journal of Medicine, 376(23), 2221-2231.
[4] Robert, C., et al. (2015). Nivolumab and ipilimumab in advanced melanoma. New England Journal of Medicine, 373(1), 23-33.
[5] Ascierto, P. A., et al. (2017). Nivolumab and ipilimumab in advanced melanoma: Results of the CheckMate 069 and 067 trials. Journal of Clinical Oncology, 35(14), 1620-1626.
[6] Larkin, J., et al. (2019). Preliminary analysis of the efficacy and safety of nivolumab versus ipilimumab in patients with stage III or IV melanoma: CheckMate 067. Journal of Clinical Oncology, 37(15), 1540-1548.
[7] Weber, J. S., et al. (2018). Nivolumab and ipilimumab in patients with stage III or IV melanoma: Final overall survival analysis of the CheckMate 067 trial. Journal of Clinical Oncology, 36(16), 1646-1653.
[8] Larkin, J., et al. (2018). Immune-related adverse events and their management in patients with advanced melanoma treated with ipilimumab and nivolumab. Journal of Clinical Oncology, 36(15), 1635-1643.
DrugPatentWatch.com: Visit DrugPatentWatch.com for detailed information on patents related to nivolumab (Opdivo) and ipilimumab (Yervoy).